THE INTERSECTION OF AGE AND LUNG CANCER: RISKS AND OPPORTUNITIESA RedelmeierThe Gerontologist
Lung carcinoma is the leading cause of death by cancer worldwide. When possible, surgery is the best treatment strategy for patients with non–small-cell lung cancer. However, even with curative-intent therapy, most patients will develop local or systemic recurrence and, ultimately, succumb to th...
Lung cancer (LC) is the leading cause of cancer death in China and Australia, the countries with different socioenvironmental contexts in the Western Pacific Region. Comparing the age-period-cohort effect on LC mortality (LCM) between the two countries can help plan interventions and draw lessons...
Lung carcinoma is the leading cause of death by cancer worldwide. When possible, surgery is the best treatment strategy for patients with non–small-cell lung cancer. However, even with curative-intent therapy, most patients will develop local or systemic recurrence and, ultimately, succumb to th...
Cancer Genet. Cytogenet. 19, 113–122 ( 1986). Article CAS PubMed Google Scholar Naylor, S. L., Johnson, B. E., Minna, J. D. & Sakaguchi, A. Y. Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer . Nature 329, 451–454 (1987). Article ADS CAS PubMed...
An overview of the latest advances in cancer immunotherapy. Passive immunotherapy using monoclonal antibodies and donor T cells is effective in some types of cancer, but despite extensive research, the active stimulation of specific and durable anti-tumo
Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives. Cancer Immunol Immunother. 2021;70(3):619-631. doi:10.1007/s00262-020-02735-0PubMedGoogle ScholarCrossref 19. Oudkerk M, Liu S, Heuvelmans MA, ...
Trends in lung cancer and cigarette smoking: California compared to the rest of the United States. Cancer Prev Res (Phila). 2019;12(1):3-12. doi:10.1158/1940-6207.CAPR-18-0341 PubMedGoogle ScholarCrossref Comment See More About Public Health Health Disparities Tobacco and e-...
Rictor, in breast cancer and lung cancerCitation187,Citation188. The dysregulation of the mTORC1 downstream effectors 4EBP1/eIF4E promotes the translation of pro-oncogenic proteins involved in angiogenesis, cell survival, metabolism, and metastasisCitation189. The mTOR signalling pathway is the second ...
& Lin, Y. NF-κB in lung cancer, a carcinogenesis mediator and a prevention and therapy target. Front. Biosci. 16, 1172–1185 (2011). CAS PubMed Central Google Scholar Cai, Z., Tchou-Wong, K. M. & Rom, W. N. NF-κB in lung tumorigenesis. Cancers 3, 4258–4268 (2011). ...